Cara Therapeutics Inc. (NASDAQ:CARA)’s share price fell 1.1% during mid-day trading on Friday . The company traded as low as $5.27 and last traded at $5.32, with a volume of 215,085 shares. The stock had previously closed at $5.38.

A number of research firms recently issued reports on CARA. Needham & Company LLC decreased their price target on shares of Cara Therapeutics from $27.00 to $23.00 and set a “buy” rating for the company in a research note on Sunday, August 7th. Stifel Nicolaus decreased their price target on shares of Cara Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a research note on Friday, August 5th. Cantor Fitzgerald reissued a “buy” rating on shares of Cara Therapeutics in a research note on Friday, August 5th. Finally, Zacks Investment Research downgraded shares of Cara Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 9th. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $21.06.

The firm’s 50-day moving average price is $5.76 and its 200 day moving average price is $5.88. The firm’s market capitalization is $145.14 million.

Cara Therapeutics (NASDAQ:CARA) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by $0.06. The firm had revenue of $0.08 million for the quarter, compared to analysts’ expectations of $0.13 million. The firm’s revenue was down 91.0% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.25) EPS. On average, analysts expect that Cara Therapeutics Inc. will post ($1.81) EPS for the current fiscal year.

Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. The Company is engaged in developing product candidates that focus on the body’s peripheral nervous system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.